SEATTLE, May 20, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of ...
The MarketWatch News Department was not involved in the creation of this content. Company reports progress to file planned IND for (Z)-endoxifen in mBC with CRO selection and streamlined development ...
SEATTLE, June 20, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat ...
Atossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE Study
SEATTLE, April 20, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), has applied to the FDA for approval to commence a clinical study of its proprietary drug, AT-H201, in COVID-19 ...
The MarketWatch News Department was not involved in the creation of this content. Recognized for Visionary Leadership and Advancing Innovative Therapies in Oncology and Healthcare Technology SEATTLE, ...
Atossa Therapeutics (NASDAQ:ATOS) added ~17% to rise sharply for the second straight session on Wednesday after announcing that enrollment in a mid-stage trial for its experimental breast cancer ...
Atossa Therapeutics, Inc. expressed disappointment over the Patent Trial and Appeal Board's ruling deeming all challenged claims of U.S. Patent No. 11,572,334 unpatentable. While Atossa will not ...
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Atossa Genetics Inc. (ATOS) one of those stocks right now? Let ...
What To Know: The FDA granted one of the biopharmaceutical company’s potential treatments, (Z)-Endoxifen, a rare pediatric disease designation for the treatment of Duchenne Muscular Dystrophy. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results